The antiviral resistance of influenza virus

Therapy

Volumn 8, Issue 6, 2011, Pages 741-762

  Escuret, Vanessa ^a,b   Ferraris, Olivier ^b   Lina, Bruno ^a,b  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ DE LYON   (France)

Author keywords

A(H1N1); A(H3N2); A(H5N1); Adamantane; Influenza B virus; Influenza viruses; Neuraminidase inhibitors; Oseltamivir; Resistance; Zanamivir

Indexed keywords

ADAMANTANE DERIVATIVE; AMANTADINE; CS 5958; DAS 181; FAVIPIRAVIR; HYBRID PROTEIN; IMMUNOGLOBULIN; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; RIBAVIRIN; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS SIALIDASE; ZANAMIVIR;

2009 H1N1 INFLUENZA; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ASSAY; CENTRAL NERVOUS SYSTEM DISEASE; DISEASE SURVEILLANCE; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; GASTROINTESTINAL SYMPTOM; GENE DELETION; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; IMMUNOSTIMULATION; INFLUENZA; INFLUENZA A; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA A (H5N1); INFLUENZA B; NONHUMAN; PROTEIN HOMEOSTASIS; REVIEW; SEASONAL INFLUENZA; SINGLE DRUG DOSE; VIRAL CLEARANCE; VIROGENESIS; VIRUS MUTATION;

EID: 81255208234     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.11.79     Document Type: Review

References (148)

1. Ferraris O, Kessler N, Lina B. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antiviral Res. 68(1), 43-48 (2005). (Pubitemid 41338581)
2. McKimm-Breschkin J, Trivedi T, Hampson A et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 47(7), 2264-2272 (2003). (Pubitemid 36753582)
3. Monto AS, McKimm-Breschkin JL, Macken C et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first years of their use. Antimicrob. Agents Chemother. 50(7), 2395-2402 (2006). (Pubitemid 43993177)
4. Sheu TG, Deyde VM, Okomo-Adhiambo M et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 52(9), 3284-3292 (2008).
5. Tashiro M, McKimm-Breschkin JL, Saito T et al. Surveillance for neuraminidaseinhibitor-resistant influenza viruses in Japan, 1996-2007. Antivir. Ther. 14(6), 751-761 (2009).
6. Whitley RJ, Hayden FG, Reisinger KS et al. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 20(2), 127-133 (2001). (Pubitemid 32151932)
7. Kiso M, Mitamura K, Sakai-Tagawa Y et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364(9436), 759-765 (2004). (Pubitemid 39165094)
8. Tamura D, Sugaya N, Ozawa M et al. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. Clin. Infect. Dis. 52(4), 432-437 (2011). n This study gives rationale for zanamivir use in pediatric patients.
9. Bright RA, Medina MJ, Xu X et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366(9492), 1175-1181 (2005). (Pubitemid 41393595)
10. Jefferson T, Demicheli V, Di Pietrantonj C, Rivetti D. Amantadine and rimantadine for influenza A in adults. Cochrane Database Syst. Rev. 2, CD001169 (2006).
11. Pielak RM, Schnell JR, Chou JJ. Mechanism of drug inhibition and drug resistance of influenza A M2 channel. Proc. Natl Acad. Sci. USA 106(18), 7379-7384 (2009).
12. Pielak RM, Chou JJ. Flu channel drug resistance: a tale of two sites. Protein Cell 1(3), 246-258 (2010).
13. Deyde VM, Xu X, Bright RA et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis. 196(2), 249-257 (2007). (Pubitemid 47047464)
14. Furuse Y, Suzuki A, Oshitani H. Large-scale sequence analysis of M gene of influenza A viruses from different species: mechanisms for emergence and spread of amantadine resistance. Antimicrob. Agents Chemother. 53(10), 4457-4463 (2009).
15. Sheu TG, Fry AM, Garten RJ et al. Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010. J. Infect. Dis. 203(1), 13-17 (2011).
16. Dawood FS, Jain S, Finelli L et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 360(25), 2605-2615 (2009).
17. Cheung CL, Rayner JM, Smith GJ et al. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis. 193(12), 1626-1629 (2006). (Pubitemid 43839465)
18. Le MT, Wertheim HF, Nguyen HD et al. Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in northern Vietnam. PLoS ONE 3(10), e3339 (2008).
19. Boltz DA, Douangngeun B, Phommachanh P et al. Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic. J. Gen. Virol. 91(Pt 4), 949-959 (2010).
20. Hersh AL, Maselli JH, Cabana MD. Changes in prescribing of antiviral medications for influenza associated with new treatment guidelines. Am. J. Pub. Health 99(Suppl. 2) S362-S364 (2009).
21. CDC. Antiviral agents for the treatment and chemoprophylaxis of influenza -recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 60(1), 1-24 (2011).
22. Boltz DA, Aldridge JR Jr, Webster RG, Govorkova EA. Drugs in development for influenza. Drugs 70(11), 1349-1362 (2010).
23. Ferraris O, Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J. Clin. Virol. 41(1), 13-19 (2008). (Pubitemid 350298978)
24. Gamblin SJ, Skehel JJ. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J. Biol. Chem. 285(37), 28403-28409 (2010).
25. Russell RJ, Haire LF, Stevens DJ et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443(7107), 45-49 (2006). (Pubitemid 44344043)
26. Colman PM, Hoyne PA, Lawrence MC. Sequence and structure alignment of paramyxovirus hemagglutininneuraminidase with influenza virus neuraminidase. J. Virol. 67(6), 2972-2980 (1993). (Pubitemid 23143664)
27. Varghese JN, McKimm-Breschkin JL, Caldwell JB, Kortt AA, Colman PM. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 14(3), 327-332 (1992).
28. von Itzstein M. The war against influenza. discovery and development of sialidase inhibitors. Nat. Rev. Drug Discov. 6(12), 967-974 (2007). nn Good review describing the discovery of NAI and structural interactions of sialic acid and NAI within the neuraminidase active site.
29. Colman PM. New antivirals and drug resistance. Ann. Rev. Biochem. 78, 95-118 (2009).
30. Lauring AS, Andino R. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog. 6(7), e1001005 (2010).
31. Wagner R, Matrosovich M, Klenk HD. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev. Med. Virol. 12(3), 159-166 (2002). (Pubitemid 34516947)
32. McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A et al. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob. Agents Chemother. 40(1), 40-46 (1996). (Pubitemid 26020747)
33. Kawai N, Ikematsu H, Iwaki N et al. Longer virus shedding in influenza B than in influenza A among outpatients treated with oseltamivir. J. Infect. 55(3), 267-272 (2007). (Pubitemid 47248483)
34. Kawai N, Ikematsu H, Hirotsu N et al. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons. Clin. Infect. Dis. 49(12), 1828-1835 (2009).
35. Potier M, Mameli L, Belisle M, Dallaire L, Melancon SB. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-a-d- Nacetylneuraminate) substrate. Anal. Biochem. 94(2), 287-296 (1979). (Pubitemid 9173017)
36. Buxton RC, Edwards B, Juo RR, Voyta JC, Tisdale M, Bethell RC. Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. Anal. Biochem. 280(2), 291-300 (2000). (Pubitemid 30308085)
37. Wetherall NT, Trivedi T, Zeller J et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J. Clin. Microbiol. 41(2), 742-750 (2003). (Pubitemid 36184190)
38. Okomo-Adhiambo M, Demmler-Harrison GJ, Deyde VM et al. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob. Agents Chemother. 54(5), 1834-1841 (2010).
39. Hurt AC, Holien JK, Parker M, Kelso A, Barr IG. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J. Virol. 83(20), 10366-10373 (2009).
40. Okomo-Adhiambo M, Nguyen HT, Sleeman K et al. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antiviral Res. 85(2), 381-388 (2010).
41. Mohr PG, Geyer H, McKimm-Breschkin JL. Mixed influenza A and B infections complicate the detection of influenza viruses with altered sensitivities to neuraminidase inhibitors. Antiviral Res. 91(1), 20-22 (2011).
42. Carr MJ, Sayre N, Duffy M, Connell J, Hall WW. Rapid molecular detection of the H275Y oseltamivir resistance gene mutation in circulating influenza A (H1N1) viruses. J. Virol. Methods 153(2), 257-262 (2008).
43. van der Vries E, Jonges M, Herfst S et al. Evaluation of a rapid molecular algorithm for detection of pandemic influenza A (H1N1) 2009 virus and screening for a key oseltamivir resistance (H275Y) substitution in neuraminidase. J. Clin. Virol. 47(1), 34-37 (2010).
44. Deyde VM, Okomo-Adhiambo M, Sheu TG et al. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antiviral Res. 81(1), 16-24 (2009).
45. Deyde VM, Sheu TG, Trujillo AA et al. Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Antimicrob. Agents Chemother. 54(3), 1102-1110 (2010).
46. Sheu TG, Deyde VM, Garten RJ, Klimov AI, Gubareva LV. Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing. Antiviral Res. 85(2), 354-360 (2010).
47. Deng YM, Caldwell N, Hurt A et al. A comparison of pyrosequencing and neuraminidase inhibition assays for the detection of oseltamivir-resistant pandemic influenza A(H1N1) 2009 viruses. Antiviral Res. 90(1), 87-91 (2011).
48. Collins PJ, Haire LF, Lin YP et al. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453(7199), 1258-1261 (2008). nn This study described precisely the structural impact of the H275Y mutation in N1. (Pubitemid 351913590)
49. Collins PJ, Haire LF, Lin YP et al. Structural basis for oseltamivir resistance of influenza viruses. Vaccine 27(45), 6317-6323 (2009).
50. Escuret V, Frobert E, Bouscambert-Duchamp M et al. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. J. Clin. Virol. 41(1), 25-28 (2008).
51. Herlocher ML, Truscon R, Elias S et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis. 190(9), 1627-1630 (2004). (Pubitemid 39411012)
52. Lackenby A, Hungnes O, Dudman SG et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro. Surveill. 13(5), 8026 (2008).
53. Meijer A, Lackenby A, Hungnes O et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis. 15(4), 552-560 (2009).
54. Dharan NJ, Gubareva LV, Meyer JJ et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 301(10), 1034-1041 (2009).
55. Hurt AC, Ernest J, Deng YM et al. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res. 83(1), 90-93 (2009).
56. Baranovich T, Saito R, Suzuki Y et al. Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season. J. Clin. Virol. 47(1), 23-28 (2010).
57. Hauge SH, Blix HS, Borgen K, Hungnes O, Dudman SG, Aavitsland P. Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007-08. Virol. J. 6(54) (2009).
58. Kramarz P, Monnet D, Nicoll A, Yilmaz C, Ciancio B. Use of oseltamivir in 12 European countries between 2002 and 2007-lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses. Euro. Surveill. 14(5), pii: 19112 (2009).
59. Baz M, Abed Y, Simon P, Hamelin ME, Boivin G. Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. J. Infect. Dis. 201(5), 740-745 (2010).
60. Rameix-Welti MA, Enouf V, Cuvelier F, Jeannin P, van der Werf S. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog. 4(7), e1000103 (2008).
61. Casalegno JS, Bouscambert-Duchamp M, Caro V et al. Oseltamivir-resistant influenza A(H1N1) viruses in south of France, 2007/2009. Antiviral Res. 87(2), 242-248 (2010).
62. Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328(5983), 1272-1275 (2010).
63. Hayden FG, de Jong MD. Emerging influenza Antiviral resistance threats. J. Infect. Dis. 203(1), 6-10 (2011). nn Concise commentary on the last threats concerning influenza antiviral resistance.
64. Eshaghi A, Bolotin S, Burton L, Low DE, Mazzulli T, Drews SJ. Genetic microheterogeneity of emerging H275Y influenza virus A (H1N1) in Toronto, Ontario, Canada from the 2007-2008 respiratory season. J. Clin. Virol. 45(2), 142-145 (2009).
65. Gerloff NA, Kremer JR, Mossong J, Opp M, Muller CP. Genomic diversity of oseltamivirresistant influenza virus A (H1N1), Luxembourg, 2007-08. Emerg. Infect. Dis. 15(9), 1523-1524 (2009).
66. Tramontana AR, George B, Hurt AC et al. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg. Infect. Dis. 16(7), 1068-1075 (2010).
67. Hill-Cawthorne GA, Schelenz S, Lawes M, Dervisevic S. Oseltamivir-resistant pandemic (H1N1) 2009 in patient with impaired immune system. Emerg. Infect. Dis. 16(7), 1185-1186 (2010).
68. Ghedin E, Laplante J, DePasse J et al. Deep sequencing reveals mixed infection with 2009 pandemic influenza A (H1N1) virus strains and the emergence of oseltamivir resistance. J. Infect. Dis. 203(2), 168-174 (2011).
69. Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. The sepsis seesaw: tilting toward immunosuppression. Nat. Med. 15(5), 496-497 (2009).
70. Gooskens J, Jonges M, Claas EC, Meijer A, Kroes AC. Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. J. Infect. Dis. 199(10), 1435-1441 (2009).
71. Moore C, Galiano M, Lackenby A et al. Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit. J. Infect. Dis. 203(1), 18-24 (2011).
72. Mandelboim M, Hindiyeh M, Meningher T, Mendelson E. Possible transmission of pandemic (HIN1) 2009 virus with oseltamivir resistance. Emerg. Infect. Dis. 16(5), 873-874 (2010).
73. Baz M, Abed Y, Papenburg J, Bouhy X, Hamelin ME, Boivin G. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N. Engl. J. Med. 361(23), 2296-2297 (2009).
74. CDC. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis -North Carolina, 2009. MMWR Morb. Mortal. Wkly. Rep. 58(35), 969-972 (2009).
75. Chen H, Cheung CL, Tai H et al. Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China. Emerg. Infect. Dis. 15(12), 1970-1972 (2009).
76. Leung TW, Tai AL, Cheng PK, Kong MS, Lim W. Detection of an oseltamivir-resistant pandemic influenza A/H1N1 virus in Hong Kong. J. Clin. Virol. 46(3), 298-299 (2009).
77. Le QM, Wertheim HF, Tran ND, van Doorn HR, Nguyen TH, Horby P. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N. Engl. J. Med. 362(1), 86-87 (2010).
78. Hurt AC, Deng YM, Ernest J et al. Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region, 2009 to 2010. Euro. Surveill. 16(3), 19770 (2011).
79. Gulland A. First cases of spread of oseltamivir resistant swine flu between patients are reported in Wales. BMJ 339, b4975 (2009).
80. Lackenby A, Moran Gilad J, Pebody R et al. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11. Euro. Surveill. 16(5), 19784 (2011).
81. Graitcer SB, Gubareva L, Kamimoto L et al. Characteristics of patients with oseltamivirresistant pandemic (H1N1) 2009, United States. Emerg. Infect. Dis. 17(2), 255-257 (2011).
82. Kiso M, Shinya K, Shimojima M et al. Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses. PLoS Pathog. 6(8), e1001079 (2010).
83. Duan S, Boltz DA, Seiler P et al. Oseltamivirresistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathog. 6(7), e1001022 (2010).
84. Memoli MJ, Davis AS, Proudfoot K et al. Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets. J. Infect. Dis. 203(3), 348-357 (2010).
85. Hamelin ME, Baz M, Abed Y et al. Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets. PLoS Pathog. 6(7), e1001015 (2010).
86. Seibert CW, Kaminski M, Philipp J et al. Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. J. Virol. 84(21), 11219-11226 (2010).
87. Campanini G, Piralla A, Rovida F et al. First case in Italy of acquired resistance to oseltamivir in an immunocompromised patient with influenza A/H1N1v infection. J. Clin. Virol. 48(3), 220-222 (2010).
88. van der Vries E, Stelma FF, Boucher CA. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N. Engl. J. Med. 363(14), 1381-1382 (2010).
89. Pizzorno A, Bouhy X, Abed Y, Boivin G. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J. Infect. Dis. 203(1), 25-31 (2011).
90. Nguyen HT, Fry AM, Loveless PA, Klimov AI, Gubareva LV. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin. Infect. Dis. 51(8), 983-984 (2010).
91. Hurt A, Lee R, Leang S et al. Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro. Surveill. 16(23), 19884 (2011).
92. Ottmann M, Duchamp MB, Casalegno JS et al. Novel influenza A(H1N1) 2009 in vitro reassortant viruses with oseltamivir resistance. Antivir. Ther. 15(5), 721-726 (2010).
93. Bastien N, Antonishyn NA, Brandt K et al. Human infection with a triple-reassortant swine influenza A(H1N1) virus containing the hemagglutinin and neuraminidase genes of seasonal influenza virus. J. Infect. Dis. 201(8), 1178-1182 (2010).
94. Ducatez MF, Sonnberg S, Hall RJ et al. Genotyping assay for the identification of 2009-2010 pandemic and seasonal H1N1 influenza virus reassortants. J. Virol. Methods 168(1-2), 78-81 (2010).
95. Abed Y, Baz M, Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir. Ther. 11(8), 971-976 (2006). (Pubitemid 44955172)
96. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z et al. Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med. 358(3), 261-273 (2008).
97. de Jong MD, Tran TT, Truong HK et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353(25), 2667-2672 (2005). (Pubitemid 41817715)
98. Le QM, Kiso M, Someya K et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437(7062), 1108 (2005). (Pubitemid 41509341)
99. Earhart KC, Elsayed NM, Saad MD et al. Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt. J. Infect. Pub. Health 2(2), 74-80 (2009).
100. Yen HL, Ilyushina NA, Salomon R, Hoffmann E, Webster RG, Govorkova EA. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J. Virol. 81(22), 12418-12426 (2007). (Pubitemid 350085855)
101. Ilyushina NA, Seiler JP, Rehg JE, Webster RG, Govorkova EA. Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets. PLoS Pathog. 6(5), e1000933 (2010).
102. Kiso M, Ozawa M, Le MT et al. Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus. J. Virol. 85(10), 4667-4672 (2011).
103. Rameix-Welti MA, Agou F, Buchy P et al. Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir. Antimicrob. Agents Chemother. 50(11), 3809-3815 (2006). (Pubitemid 44684897)
104. Orozovic G, Orozovic K, Lennerstrand J, Olsen B. Detection of resistance mutations to antivirals oseltamivir and zanamivir in avian influenza A viruses isolated from wild birds. PLoS ONE 6(1), e16028 (2011).
105. Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, Barr IG. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res. 73(3), 228-231 (2007).
106. Varghese JN, Smith PW, Sollis SL et al. Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure 6(6), 735-746 (1998). (Pubitemid 28301207)
107. Herlocher ML, Carr J, Ives J et al. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res. 54(2), 99-111 (2002). (Pubitemid 34327688)
108. Yen HL, Herlocher LM, Hoffmann E et al. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother. 49(10), 4075-4084 (2005). (Pubitemid 41400949)
109. Hurt AC, Nor'e SS, McCaw JM et al. Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitivemixtures model. J. Virol. 84(18), 9427-9438 (2010).
110. Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob. Agents Chemother. 49(11), 4515-4520 (2005). (Pubitemid 41552580)
111. Carr S, Ilyushina NA, Franks J et al. Oseltamivir-resistant influenza A and B viruses pre-and postantiviral therapy in children and young adults with cancer. Pediatr. Infect. Dis. J. 30(4), 284-288 (2011). n Report of NAI-resistant influenza B viruses in untreated patients suggesting a possible person-to-person transmission of these resistant viruses.
112. Ruiz-Carrascoso G, Casas I, Pozo F, Gonzalez-Vincent M, Perez-Brena P. Prolonged shedding of amantadine-and oseltamivir-resistant influenza A(H3N2) virus with dual mutations in an immunocompromised infant. Antivir. Ther. 15(7), 1059-1063 (2010).
113. Bouvier NM, Lowen AC, Palese P. Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol. J. Virol. 82(20), 10052-10058 (2008).
114. Baz M, Abed Y, McDonald J, Boivin G. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin. Infect. Dis. 43(12), 1555-1561 (2006). (Pubitemid 44901897)
115. Simon P, Holder BP, Bouhy X, Abed Y, Beauchemin CA, Boivin G. The I222V neuraminidase mutation has a compensatory role in replication of an oseltamivir-resistant influenza virus A/H3N2 E119V mutant. J. Clin. Microbiol. 49(2), 715-717 (2011).
116. Richard M, Ferraris O, Erny A et al. Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir. Antimicrob. Agents Chemother. 55(6), 2942-2952 (2011).
117. Abed Y, Nehme B, Baz M, Boivin G. Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. Antiviral Res. 77(2), 163-166 (2008).
118. Abed Y, Baz M, Boivin G. A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus. J. Infect. Dis. 199(2), 180-183 (2009).
119. Memoli MJ, Hrabal RJ, Hassantoufighi A et al. Rapid selection of a transmissible multidrug-resistant influenza A/H3N2 virus in an immunocompromised host. J. Infect. Dis. 201(9), 1397-1403 (2010).
120. Ferraris O, Kessler N, Valette M, Lina B. Evolution of the susceptibility to antiviral drugs of A/H3N2 influenza viruses isolated in France from 2002 to 2005. Vaccine 24(44-46), 6656-6659 (2006). (Pubitemid 46127439)
121. Moules V, Ferraris O, Terrier O et al. In vitro characterization of naturally occurring influenza H3NA-viruses lacking the NA gene segment: toward a new mechanism of viral resistance?. Virology 404(2), 215-224 (2010).
122. Sugaya N, Mitamura K, Yamazaki M et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin. Infect. Dis. 44(2), 197-202 (2007). (Pubitemid 46079980)
123. Hatakeyama S, Sugaya N, Ito M et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 297(13), 1435-1442 (2007). n Report of NAI-resistant influenza B viruses in untreated patients suggesting a possible person-to-person transmission of these resistant viruses. (Pubitemid 46556469)
124. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178(5), 1257-1262 (1998).
125. Gubareva LV. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res. 103(1-2), 199-203 (2004). (Pubitemid 38649080)
126. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J. Infect. Dis. 193(6), 760-764 (2006).
127. Hurt AC, Iannello P, Jachno K et al. Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient. Antimicrob. Agents Chemother. 50(5), 1872-1874 (2006).
128. Oakley AJ, Barrett S, Peat TS et al. Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. J. Med. Chem. 53(17), 6421-6431 (2010).
129. Regoes RR, Bonhoeffer S. Emergence of drug-resistant influenza virus: population dynamical considerations. Science 312(5772), 389-391 (2006).
130. Esposito S, Molteni CG, Colombo C et al. Oseltamivir-induced resistant pandemic A/H1N1 influenza virus in a child with cystic fibrosis and Pseudomonas aeruginosa infection. J. Clin. Virol. 48(1), 62-65 (2010).
131. Dulek DE, Williams JV, Creech CB et al. Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. Clin. Infect. Dis. 50(11), 1493-1496 (2010).
132. Gaur AH, Bagga B, Barman S et al. Intravenous zanamivir for oseltamivirresistant 2009 H1N1 influenza. N. Engl. J. Med. 362(1), 88-89 (2010).
133. Mancuso CE, Gabay MP, Steinke LM, Vanosdol SJ. Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza. Ann. Pharmacother. 44(7-8), 1240-1249 (2010).
134. Renaud C, Pergam SA, Polyak C et al. Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir. Transpl. Infect. Dis. 12(6), 513-517 (2010).
135. Nguyen JT, Hoopes JD, Le MH et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS ONE 5(2), e9332 (2010).
136. Duval X, van der Werf S, Blanchon T et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med. 7(11), e1000362 (2010).
137. Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob. Agents Chemother. 53(1), 186-192 (2009).
138. Nguyen HT, Sheu TG, Mishin VP, Klimov AI, Gubareva LV. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob. Agents Chemother. 54(9), 3671-3677 (2010).
139. Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob. Agents Chemother. 54(6), 2575-2582 (2010).
140. Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial. Clin. Infect. Dis. 51(10), 1167-1175 (2010).
141. Sidwell RW, Barnard DL, Day CW et al. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob. Agents Chemother. 51(3), 845-851 (2007). (Pubitemid 46355265)
142. Kiso M, Takahashi K, Sakai-Tagawa Y et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc. Natl Acad. Sci. USA 107(2), 882-887 (2010).
143. Belser JA, Lu X, Szretter KJ et al. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J. Infect. Dis. 196(10), 1493-1499 (2007). (Pubitemid 351411986)
144. Triana-Baltzer GB, Gubareva LV, Nicholls JM et al. Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS ONE 4(11), e7788 (2009).
145. Stouffer AL, Acharya R, Salom D et al. Structural basis for the function and inhibition of an influenza virus proton channel. Nature 451(7178), 596-599 (2008). (Pubitemid 351186271)
146. Schnell JR, Chou JJ. Structure and mechanism of the M2 proton channel of influenza A virus. Nature 451(7178), 591-595 (2008). (Pubitemid 351186272)
147. Burmeister WP, Ruigrok RW, Cusack S. The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J. 11(1), 49-56 (1992).
148. Hurt AC, Barr IG, Hartel G, Hampson AW. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antiviral Res. 62(1), 37-45 (2004). (Pubitemid 38340746)